Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming presentations at the ...

Mayo Clinic in Arizona has two campuses. The largest is in north Phoenix, where a big expansion is underway. Here's what to ...

Author Jo Giese outlines in her new book how, after a botched surgery, she lost her left Achilles and relearned to walk ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...

Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development organization, today announced a strategic partnership ...

None ...

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group. Biodexa Pharmaceuticals PLC (Nasdaq ...

Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well ...

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now ...

Once synonymous with hard hats and tool belts, apprenticeships are branching into health care, artificial intelligence, ...

Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 ...

The majority of us have used such services as Uber or Airbnb, which provide a new and easy way of conducting business between ...